NEW YORK (GenomeWeb News) – Sequenom today said that it has inked a contract with sales and marketing services firm PDI to provide the sales force that will launch and commercialize the firm's SEQureDx non-invasive prenatal genetic screening tests.

PDI will work with the Sequenom Center for Molecular Medicine, the clinical lab subsidiary of Sequenom, in supporting commercialization of the firm's Rhesus D genotyping test, its Down syndrome test, and other laboratory-developed tests. The partners will hire, train, and develop a sales team for the SCMM.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.